611
/ 3SBio
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
29
Go to page
1
2
December 04, 2025
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
(clinicaltrials.gov)
- P3 | N=243 | Active, not recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis
November 21, 2025
Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P2 | N=142 | Completed | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting ➔ Completed
Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
November 21, 2025
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=510 | Active, not recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Trial primary completion date: Sep 2025 ➔ Dec 2025 | Recruiting ➔ Active, not recruiting
Enrollment closed • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
November 19, 2025
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=180 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
November 19, 2025
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P3 | N=594 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
July 22, 2025
Late Breaking Abstract - A phase 2 study of a new humanized anti-IL-4Rα mAb (SSGJ-611) in COPD
(ERS 2025)
- P2 | "Meanwhile, advent events were comparable across the three groups. Conclusion As a novel anti-IL-4Rα mAb targeting type 2 inflammation, we have preliminarily demonstrated the efficacy and safety of SSGJ-611 in COPD with frequent exacerbation."
Late-breaking abstract • P2 data • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Respiratory Diseases
July 14, 2025
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=400 | Active, not recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
August 07, 2025
A randomized, double-blinded, placebo-controlled phase III clinical trial, to evaluate the safety and efficacy of 611(Recombinant anti-IL-4Rα humanized monoclonal antibody) in Chinese adults with moderate to severe chronic obstructive pulmonary disease (COPD)
(ChiCTR)
- P3 | N=570 | Not yet recruiting | Sponsor: Shenzhen People's Hospital; Shenzhen People's Hospital
New P3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
July 08, 2025
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P1/2 | N=124 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2024 ➔ Aug 2026 | Trial primary completion date: Aug 2024 ➔ Aug 2026
Enrollment open • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
June 27, 2025
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
(clinicaltrials.gov)
- P1 | N=180 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
June 27, 2025
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=180 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
June 27, 2025
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P3 | N=594 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
March 10, 2025
Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial.
(PubMed, Dermatol Ther (Heidelb))
- P2 | "611 demonstrated a high efficacy and a favorable safety profile in patients with moderate-to-severe AD."
Clinical • Journal • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Pruritus • Respiratory Diseases • IL13
October 15, 2024
A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps
(clinicaltrials.gov)
- P3 | N=240 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P3 trial • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis
October 01, 2024
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=400 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
August 15, 2024
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=400 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Combination therapy • New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
June 06, 2024
Efficacy and safety of 611 for the treatment of moderate-to-severe atopic dermatitis in adults
(BAD 2024)
- "611 showed a positive effect in treatment of patients with moderate-to-severe AD in terms of efficacy and safety. 611 has potentially become a promising treatment product targeting IL-4Rα, following on from dupilumab."
Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Pruritus • IL13 • IL4
March 22, 2024
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P1/2 | N=104 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
February 01, 2024
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=510 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
February 01, 2024
Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P2 | N=150 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
February 01, 2024
SSGJ-611-AD-II-01: Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=93 | Completed | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting ➔ Completed
Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
January 12, 2024
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
(clinicaltrials.gov)
- P2 | N=90 | Active, not recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis
December 15, 2023
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=510 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
October 25, 2023
Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P2 | N=150 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
May 19, 2023
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
(clinicaltrials.gov)
- P2 | N=90 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P2 trial • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis
1 to 25
Of
29
Go to page
1
2